Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 6:2022:2574451.
doi: 10.1155/2022/2574451. eCollection 2022.

Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer

Qing Gu  1 , Shu'e Li  1
Affiliations

Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer

Qing Gu et al. Contrast Media Mol Imaging. .

Abstract

This study was to evaluate the clinical efficacy of pemetrexed combined with platinum-based chemotherapy in the treatment of elderly lung cancer using electronic computed tomography (CT) images based on artificial intelligence algorithms. In this study, 80 elderly patients with lung cancer treated were selected and randomly divided into two groups: patients treated with pemetrexed combined with cisplatin were included in the pemetrexed group and patients treated with docetaxel combined with cisplatin were included in the docetaxel group, with 40 cases in each group. The DenseNet network was compared with the Let Net-5 and ResNet model and applied to the CT images of 80 elderly patients with lung cancer. The diagnosis accuracy of the DenseNet network (97.4%) was higher than that of the Let Net-5 network (80.1%) and ResNet model (95.5%). Carcinoembryonic antigen (CEA), cytokeratin fragment antigen 21-1 (CYFRA 21-1), and squamous cell-associated antigen (SCC) after chemotherapy in the pemetrexed group and docetaxel group were all lower than those before chemotherapy, showing statistically obvious differences (P < 0.05). The satisfaction degree of nursing care in the pemetrexed group (92.67%) was significantly higher than that in the docetaxel group (85.62%), and the difference was statistically significant (P < 0.05). Adverse reactions such as fatigue, diarrhea, and neutrophils in the pemetrexed group were lower than those in the docetaxel group, and the difference was statistically great (P < 0.05). The DenseNet convolutional neural network has high diagnostic accuracy; methotrexate combined with platinum chemotherapy can improve the chemotherapy effect in elderly patients with lung cancer, with low degree of adverse reactions and good overall tolerance, which can be used as the first-line treatment for elderly patients with lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The dense connection mechanism of the DenseNet.
Figure 2
Figure 2
Comparison of the diagnostic test results of lung malignant nodules.
Figure 3
Figure 3
Comparison of CT image segmentation results. (a) Original CT image; (b) Image segmented by Let Net-5 network; (c) Image segmented by ResNet; (d) Image segmented by the DenseNet.
Figure 4
Figure 4
Comparison of clinical efficacy between two groups. (a) Comparison of clinical efficacy; (b) Comparison of survival.
Figure 5
Figure 5
Changes in lung cancer CT images before and after chemotherapy. Male, 79 years old, patient with lung cancer. (a) Before chemotherapy, the CT image showed the distribution of nodular soft tissue density masses at the posterior and lower right hilum (the size was about 0.8 cm in diameter, the edges were slightly under-rectified, and there was no obvious swollen lymphoma in the mediastinum). (b) After chemotherapy, CT images showed that the posterior and lower right hilum nodules were significantly smaller than before treatment, with a diameter of about 0.4 cm, blurred edges, reduced right lung volume, and no obvious lymphadenopathy in the mediastinum.
Figure 6
Figure 6
Tumor marker levels before and after treatment. ∗Compared with the levels before treatment, P < 0.05.
Figure 7
Figure 7
Comparison of nursing satisfaction. ∗Compared with the pemetrexed group, P < 0.05.
Figure 8
Figure 8
Comparison of adverse reactions between the two groups. ∗Compared with the pemetrexed group, P < 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mok T. S., Wu Y.-L., Ahn M.-J., et al. New England Journal of Medicine . 2017 February 16;376(7):629–640. doi: 10.1056/NEJMoa1612674. - DOI - PMC - PubMed
    1. Papadimitrakopoulou V. A., Mok T. S., Han J. Y., et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of Oncology . 2020 November;31(11):1536–1544. doi: 10.1016/j.annonc.2020.08.2100. - DOI - PubMed
    1. Garassino M. C., Gadgeel S., Esteban E., et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology . 2020 March;21(3):387–397. doi: 10.1016/S1470-2045(19)30801-0. - DOI - PubMed
    1. Nishio M., Saito H., Goto K., et al. Cancer Science . 4. Vol. 112. PMCID; 2021. IMpower132: atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients; pp. 1534–1544. - DOI - PMC - PubMed
    1. Papadimitrakopoulou V. A., Han J. Y., Ahn M. J., et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer . 2020 January 15;126(2):373–380. doi: 10.1002/cncr.32503. - DOI - PubMed